The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Self-citationRubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationMaira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Self-citationMutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationSugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I., & Taguchi, K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2584::aid-cncr22>3.0.co;2-5 · Cited by 795
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Self-citationTargeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Self-citationKurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Self-citationChan, J. K., Teoh, D., Hu, J. M., Shin, J. Y., Osann, K., & Kapp, D. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.006 · Cited by 450
Origins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Goff, B. A., Sainz de la Cuesta, R., Muntz, H. G., Fleischhacker, D., Ek, M., Rice, L. W., Nikrui, N., Tamimi, H. K., Cain, J. M., Greer, B. E., et al. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0065 · Cited by 352
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Takano, M., Kikuchi, Y., Yaegashi, N., Kuzuya, K., Ueki, M., Tsuda, H., Suzuki, M., Kigawa, J., Takeuchi, S., Tsuda, H., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603116 · Cited by 266
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Pectasides, D., Fountzilas, G., Aravantinos, G., Kalofonos, H. P., Efstathiou, E., Salamalekis, E., Farmakis, D., Skarlos, D., Briasoulis, E., Economopoulos, T., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.056 · Cited by 215
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
Kuo, K.-T., Guan, B., Feng, Y., Mao, T.-L., Chen, X., Jinawath, N., Wang, Y., Kurman, R. J., Shih, I.-M., & Wang, T.-L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3913 · Cited by 196
Self-citationEnomoto, T., Weghorst, C. M., Inoue, M., Tanizawa, O., & Rice, J. M. (1991) · PubMed Central · Cited by 192
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Self-citationp53 mutation is a common genetic event in ovarian carcinoma.
Milner, B. J., Allan, L. A., Eccles, D., Kitchener, H. C., Léonard, R., Kelly, K. F., Parkin, D. E., & Haites, N. E. (1993) · PubMed · Cited by 175
Schnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
Crotzer, D. R., Sun, C. C., Coleman, R. L., Wolf, J. K., Levenback, C. F., & Gershenson, D. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.024 · Cited by 147
Pectasides, D. G., Fountzilas, G., Aravantinos, G., Kalofonos, C. P., Efstathiou, H., Farmakis, D. T., Skarlos, D., Pavlidis, N., Economopoulos, T., & Dimopoulos, M. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.038 · Cited by 141
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 124
Salani, R., Kurman, R. J., Giuntoli, R. L., Gardner, G. J., Bristow, R. E., Wang, T., & Shih, I. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01039.x · Cited by 120
Self-citationPrevo, R., Deutsch, É., Sampson, O. L., Diplexcito, J., Cengel, K. A., Harper, J. V., O’Neill, P., McKenna, W. G., Patel, S. K., & Bernhard, E. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0757 · Cited by 118
Ovarian clear cell adenocarcinoma: a continuing enigma: Table 1
Tan, D. S. P., & Kaye, S. B. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040030 · Cited by 117
PIK3CA mutations in advanced ovarian carcinomas
Wang, Y., Helland, Å., Holm, R., Kristensen, G. B., & Børresen‐Dale, A. (2005) · Human Mutation · doi:10.1002/humu.9316 · Cited by 117
Takano, M., Sugiyama, T., Yaegashi, N., Sakuma, M., Suzuki, M., Saga, Y., Kuzuya, K., Kigawa, J., Shimada, M., Tsuda, H., et al. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01158.x · Cited by 95
p53 Mutation Is Infrequent in Clear Cell Carcinoma of the Ovary
Ho, E. S., Lai, C., Hsieh, Y.-T., Chen, J., Lin, A.-J., Hung, M., & Liu, F.-S. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6025 · Cited by 94
Common Genetic Changes between Endometriosis and Ovarian Cancer
小畑, 孝., & Hoshiai, H. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000052877 · Cited by 93
Stücklin, A. G., Fattet, S., Fischer, B. E., Shalaby, T., Jackson, S. P., Schoenwaelder, S. M., Grotzer, M. A., Delattre, O., & Arcaro, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0385 · Cited by 77
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Self-citationARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationOvarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Metadata
- Authors
- Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., & Shih, I.-M.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 174
- Issue
- 5
- Pages
- 1597-1601
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2048677309
- Cited by
- 485
- References
- 39
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.